Digest Network Come funziona
Network
/
Società
Re
Non verificato

RevBio, Inc.

Di cosa scriviamo

BiotecnologiaIgiene alimentareIndustriaMedicina alternativaMultimedialità

7 comunicati stampa

Guarda tutti i comunicati
04/11/2025
RevBio® Receives First FDA Approval for a "Bone Glue" to Treat Extremity Fractures in a Clinical Trial
Fonte
RevBio, Inc.
Emittente
Business Wire
1.00
0
06/10/2025
RevBio Receives a $2.2 Million Phase II NIH Grant to Further Develop the Minimally Invasive Use of TETRANITE® to Treat Complex Spine Fractures
Fonte
RevBio, Inc.
Emittente
Business Wire
1.00
0
29/05/2025
RevBio Expands Globally into the United Kingdom with its Second Cranial Flap Fixation Clinical Trial for its Regenerative Bone Adhesive
Fonte
RevBio, Inc.
Emittente
Business Wire
1.00
0
17/03/2025
Multimedialità
Industria
Scienza
Attrezzature medico-sanitarie
Medicina - Varie
Igiene alimentare
Odontoiatria
Biotecnologia
Medicina alternativa
Salute
RevBio Initiates its Pivotal Clinical Trial in Europe for its Dental Implant Stabilization Product
Fonte
RevBio, Inc.
Emittente
Business Wire
1.00
0
30/01/2025
RevBio Issued a Key Patent for its Regenerative Bone Adhesive Technology by the United States Patent and Trademark Office
Fonte
RevBio, Inc.
Emittente
Business Wire
1.00
0
11/12/2024
Multimedialità
Industria
Sanità
Scienza
Attrezzature medico-sanitarie
Medicina - Varie
Biotecnologia
Medicina alternativa
Igiene alimentare
Salute
RevBio Receives Both FDA Approval to Expand its Clinical Trial and CMS Reimbursement for its Regenerative Bone Adhesive for Cranial Flap Fixation
Fonte
RevBio, Inc.
Emittente
Business Wire
1.00
0
16/09/2024
RevBio Receives a $2.4 Million NIH Grant to Conduct a First-in-Human Clinical Trial for its Regenerative Bone Adhesive for Cranial Flap Fixation and Enrolls First Five Patients
Fonte
RevBio, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0